Trial
NCT04984330
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
Early Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Karyopharm Therapeutics Inc
Condition
Amyloid
Intervention
Selinexor
Why stopped
Funding withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-17